Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin

J Winer, M Zenati, L Ramalingam, H Jones… - Annals of surgical …, 2014 - Springer
Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion
(HIPEC) for peritoneal carcinomatosis (PC) of colorectal origin increases survival (OS) …

Actual 5-year survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis of colorectal origin

E Sarfaty, N Khajoueinejad, AT Yu, S Hiotis… - Annals of Surgical …, 2024 - Springer
Background Cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC)
improves survival compared with chemotherapy alone in patients with peritoneal …

Sites of recurrence after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis from colorectal and …

Y Feferman, D Solomon, S Bhagwandin, J Kim… - Annals of Surgical …, 2019 - Springer
Background This report describes patterns of disease recurrence after optimal cytoreduction
(CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal …

[HTML][HTML] Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study

L Solaini, F D'Acapito, A Passardi, M Framarini… - World journal of surgical …, 2019 - Springer
Background In this study, we report our experience of cytoreductive surgery plus
hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) in patients with peritoneal …

[HTML][HTML] Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian …

MCC Teo, GHC Tan, C Lim, CS Chia, CK Tham… - Asian Journal of …, 2015 - Elsevier
Introduction Compared with intravenous chemotherapy, cytoreductive surgery (CRS) and
hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to improve survival in …

[HTML][HTML] Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a …

CQ Huang, XJ Yang, Y Yu, HT Wu, Y Liu… - PLOS …, 2014 - journals.plos.org
Background Peritoneal carcinomatosis (PC) is a difficult clinical challenge in colorectal
cancer (CRC) because conventional treatment modalities could not produce significant …

[HTML][HTML] Status of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer

SY Yang, JH Kang, HS Kim, YD Han… - Journal of …, 2019 - ncbi.nlm.nih.gov
Peritoneal carcinomatosis (PC) was previously considered an incurable disease with a poor
survival outcome. As our understanding of its biology evolved, the paradigm of the …

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer

MK Gervais, P Dubé, Y McConnell… - Journal of Surgical …, 2013 - Wiley Online Library
Background Peritoneal carcinomatosis (PC) from colorectal cancer is associated with a poor
prognosis. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy …

Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of …

HJ Braam, TR Van Oudheusden… - Journal of surgical …, 2014 - Wiley Online Library
Abstract Background and Objectives CytoReductive Surgery (CRS) combined with
Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) has an established role in the …

Comparison of survival in patients with isolated peritoneal carcinomatosis from colorectal cancer treated with cytoreduction and melphalan or mitomycin‐C as …

A Sipok, A Sardi, C Nieroda, MC King… - … Journal of Surgical …, 2018 - Wiley Online Library
Background. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal
carcinomatosis (PC) from colorectal cancer (CRC) is debated. Melphalan as a perfusion …